Table 3. Univariate analysis of overall survival (n=44).

Clinical pathological factor	HR	95% CI	P value
Agent (Pembro vs. Nivo)	0.30	0.09–1.01	0.052
Pathological type (Ad vs. Sq)	5.60	1.03–5.83	0.043
PS (0.1 vs. 2)	4.29	1.80 –10.25	0.001
PET (SUV) (SD)	1.98	1.61−3.37	0.012
WBC (SD)	2.38	1.39–4.00	0.002
Neutro (SD)	2.49	1.44–4.30	0.001
NLR (SD)	2.07	1.24–3.45	0.050
LDH (SD)	2.22	1.41−3.47	10
Alb (SD)	0.41	0.25–0.65	0.0

Pembro, pembrolizumab; Nivo, nivolumab; Ad, adenocarcinoma; Sq, squamous cell carcinoma; PS, performance status; PET, positron emission tomography; SUV, standardized uptake value; SD, standard deviation; WBC, white blood cell; Neutro, neutrophil; NLR, neutrophil-to-lymphocyte ratio; LDH, lactate dehydrogenase; alb, albumin.